SINGAPORE, Sept. 29, 2014 /CNW/ - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I.F), a developer of leading-edge photonics technologies for industrial,
healthcare and scientific markets, today announced that its new
configuration of LFS scintillation crystals (LFS-3 plates) will be
assessed by CERN scientists in the Large Hadron Collider. As
previously announced on July 28, 2014, the Compact Muon Solenoid (CMS)
Experiment successfully tested the specially designed LFS-3 plates.
Due to the high quality performance of the individual plates, the
scientific team at CERN has ordered enough LFS-3 plates to build
initial modules which will be installed in the Large Hadron Collider
and subjected to a high energy beam.
"We have successfully made it to the final technical evaluation stage
before approval can be given for full adoption of our LFS-3 plates for
large scale CERN experiments," said Dr. A.F. Zerrouk, Chairman,
President, and CEO of Zecotek Photonics Inc. "High light yield and
radiation tolerance are the key performance criteria of our LFS-3
plates, and we expect to see the new design meet the strict parameters
required by CERN experiments. We very much look forward to playing a
major role in the advancement of scientific research at CERN and for
Zecotek to be able to capitalize on the unique commercial value of its
patented LFS scintillation crystal."
The CMS Experiment is one of two large general-purpose particle physics
detectors built on the Large Hadron Collider at CERN in Europe. It is
composed of three main components: scintillation material,
photo-detectors and the ubiquitous electronic system. Zecotek's new
LFS-3 plates are prime candidates for use in CERN's high energy
experiments because of their density of material, stopping power, fast
decay time, very good energy resolution, and radiation hardness.
Experiments can also benefit from Zecotek's LFS-3 plates due to reduced
labour and re-calibration costs associated with single crystal forms,
as well as reduced interruptions associated with the maintenance and
refitting of damaged crystals.
In March 2013, CERN scientists confirmed that a new subatomic particle
discovered at the world's most powerful particle accelerator is the
Higgs Boson. As CERN pushes into this new frontier of science,
additional experiments are required to determine the particle's
properties and its true form. High-energy scintillation crystals with
high radiation hardness and solid-state photo detectors are paramount
for the success of the next stage of experiments.
About the CMS Experiment at CERN
CMS is one of two general-purpose experiments at CERN's Large Hadron
Collider (LHC) that have been built to search for new physics. CMS is
designed to detect a wide range of particles and phenomena produced in
the LHC's high-energy proton-proton and heavy-ion collisions. At CMS,
scientists are looking into the unknown and trying to answer the most
fundamental questions about our Universe, for example: "What is the Universe really made of and what forces act within it?" and
"What gives everything substance?". CMS also measures the properties of well-known particles with
unprecedented precision and is on the lookout for completely new,
unpredicted phenomena. Such research not only increases our
understanding but may eventually spark new technologies that could
change the world we live in. The CMS experiment is one of the largest
international scientific collaborations in history, involving 4300
particle physicists, engineers, technicians, students and support staff
from 179 universities and institutes in 41 countries. For more
information about CMS please visit http://cms.web.cern.ch.
Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics
technology company developing high-performance scintillation crystals,
photo detectors, positron emission tomography scanning technologies, 3D
auto-stereoscopic displays, and lasers for applications in medical,
high-tech and industrial sectors. Founded in 2004, Zecotek operates
three divisions: Imaging Systems, Laser Systems and 3D Display Systems
with labs located in Canada, Korea, Russia, Singapore and U.S.A. The
management team is focused on building shareholder value by
commercializing over 50 patented and patent pending novel photonic
technologies directly and through strategic alliances and joint
ventures with leading industry partners such as Hamamatsu Photonics
(Japan), the European Organization for Nuclear Research (Switzerland),
Beijing Opto-Electronics Technology Co. Ltd. (China), NuCare Medical
Systems (South Korea), and National NanoFab Center (South Korea). For
more information visit www.zecotek.com, follow @zecotek on Twitter.
This press release may contain forward-looking statements that are based
on management's expectations, estimates, projections and assumptions.
These statements are not guarantees of future performance and involve
certain risks and uncertainties, which are difficult to predict.
Therefore, actual future results and trends may differ materially from
what may have been stated.
The TSX Venture 50® are the top 10 companies listed on the TSX Venture
Exchange, in each of five major industry sectors - mining, oil & gas,
technology & life sciences, diversified industries and clean technology
- based on a ranking formula with equal weighting given to return on
investment, market cap growth, trading volume and analyst coverage. All
data was as of December 31, 2013.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of the content of
this news release. If you would like to receive news from Zecotek in
the future please visit the corporate website at www.zecotek.com.
SOURCE: Zecotek Photonics Inc.
For further information:
Zecotek Photonics Inc.
Unit 1120 - 21331 Gordon Way
Richmond, BC V6W 1J9
T: (604) 783-8291